8 New Atrial Fibrillation Treatment and diagnosis options.

Atrial Fibrillation treatment and diagnosis is getting better.

Why? Because we have an aging population, technology is getting better, we are learning more about atrial fibrillation, afibbers are increasing in number and therefore there is more data available and the segment of adult CHD(congenital heart defect) survivors is also getting bigger.

Have you heard of these new atrial fibrillation treatment and diagnosis breakthroughs? Read on….

SK Channels

Currently, the first “in-man” randomized, double-blind, placebo-controlled single ascending dose study to assess the safety of a new drug called AP30663 is being carried out. It is done by The Centre for Human Drug Research (CHDR) in the Netherlands.

The Danish biotech company Ascesion Pharma who is busy with the study say’s it is based on inhibition of SK Channels.

According to epmmagazine.com: “Through blocking these channels with a functionally atrial selective drug helps to avoid the deleterious effects on the ventricles, thereby offers a novel and promising approach for an effective AF treatment with an anticipated higher safety and tolerability profile.”